Bioforce Nanosciences Holdings (BFNH) Change in Accured Expenses (2019 - 2026)

Bioforce Nanosciences Holdings has disclosed Change in Accured Expenses across 8 years of filings, most recently posting $101250.0 for Q1 2026.

• Quarterly Change in Accured Expenses fell 4.26% year-over-year to $101250.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1500.0 (down 100.35% YoY) and the FY2025 annual result came in at $3000.0, down 99.29% from the prior year.
• Change in Accured Expenses rose to $101250.0 in Q1 2026, from -$313051.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $323163.0 in Q3 2022 and troughed at -$314999.0 in Q4 2023.
• A 5-year average of $56029.5 and a median of $105750.0 in 2022 frame the typical range for Change in Accured Expenses.
• Biggest YoY gain for Change in Accured Expenses was 26337.5% in 2023; the steepest drop was 397.87% in 2023.
• Tracing BFNH's Change in Accured Expenses over 5 years: stood at $105750.0 in 2022, then tumbled by 397.87% to -$314999.0 in 2023, then soared by 133.57% to $105750.0 in 2024, then tumbled by 396.03% to -$313051.0 in 2025, then surged by 132.34% to $101250.0 in 2026.
• Business Quant data shows BFNH's Change in Accured Expenses at $101250.0 in Q1 2026, -$313051.0 in Q4 2025, and $314421.0 in Q3 2025.